Inventiva: second tranche drawn from the EIB
Disbursement of this second tranche, which carries an interest rate of 7% p.a., is scheduled for January 18. On January 4, in accordance with the financing agreement, the biopharmaceutical company issued 3,144,654 warrants reserved for the EIB.
Inventiva will use the proceeds of this drawdown to finance part of the ongoing pivotal Phase III clinical trial evaluating lanifibranor in NASH. These 25 million euros confirm the company's estimated cash flow horizon of early Q3 2024.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction